Mesoblast limited (ASX:MSB) shares passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.42 and traded as low as $1.94. Mesoblast shares last traded at $2.12, with a volume of 3,697,999 shares.
The company has a debt-to-equity ratio of 16.90, a quick ratio of 1.21 and a current ratio of 1.41. The stock’s 50 day simple moving average is A$1.48 and its two-hundred day simple moving average is A$1.42. The firm has a market capitalization of $1.05 billion and a PE ratio of -11.65.
About Mesoblast (ASX:MSB)
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Recommended Story: Why Net Income is Important to Investors
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.